… The article describes current stent modifications to decrease the number of stent … tial of
drug—eluting stents and stentgrafts in SFA treat— ment. Stent design alterations to prevent stent …

… Because DES with active stent coatings have shown to be beneficial in the treatment of
coronary artery disease}5 the applicability of these drug coatings for the treatment of femoro-…

… with a paclitaxel-coated balloon is … therapy that, especially in cases of noncomplex lesions,
obviates the need for permanent implants such as BMSs, stent grafts, and drug-eluting stents (…

… Although no large randomized trials have been published comparing DCB with bare-metal
stents, drug-eluting stents, or atherectomy, the IN.PACT Admiral DCB results compare …

… complex SFA lesions (≥60 mm lesions length, heavily calcified, and/or CTO) [14]. Delivery
… antiproliferative drugs to the target lesion using drug coated stents (DCS) and drug-coated …

… and drug-eluting stents have improved long-term outcomes in patients undergoing endovascular
therapy for femoropopliteal lesions. Furthermore, cilostazol reduces in-stent restenosis (…

… Therefore the concept of using a balloon catheter to directly deliver an antiproliferative drug
… therapy, and this concept of non-stent based local drug delivery by a drug coated balloon (…

… vasculature, limus-based drug-eluting stents (DES) have … have been reported for a
paclitaxel-eluting polymer-free nitinol self-… DAPT in patients treated with PEB and stent …

… bare metal stents and drug-eluting stents … treatment for superficial femoral and popliteal
artery disease remains controversial. Some practice guidelines advise against primary stenting …

… In this setting, different treatment options are available and drug-coated balloons (DCBs) …
for the treatment of SFA ISR. The available data demonstrate that SFA ISR can be safely treated …